13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001766721
Total reported value
$471.6M
$471.6M
13 檔
58.5%
The Q1 2025 SEC filing reveals that Aisling Capital Management LP held a total portfolio value of $471.6M, covering 13 public equity positions.
In Q1 2025, Aisling Capital Management LP displayed an active expansion posture, initiating 13 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 72.72% | -6.87% | — | |
| 2 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 13.54% | — | -44.83% | |
| 3 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 4.36% | -0.36% | — | |
| 4 | BCAX | Bicara Therapeutics Inc | Stock-Other | 2.57% | +1.20% | — | |
| 5 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 2.37% | +2.61% | — | |
| 6 | NUVB | Nuvation Bio Inc | Stock-Other | 1.55% | — | — | |
| 7 | CMPS | Compass Pathways PLC | Stock-Other | 1.19% | +2.64% | +24.25% | |
| 8 | BMEA | Biomea Fusion Inc | Stock-Other | 0.59% | -0.02% | — | |
| 9 | CALC | Calcimedica Inc | Stock-Other | 0.35% | — | — | |
| 10 | ✓ | Elevation Oncology Inc | Stock-Other | 0.25% | — | — | |
| 11 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 0.23% | +0.15% | — | |
| 12 | MRKR | Marker Therapeutics Inc | Stock-Other | 0.14% | +0.01% | — | |
| 13 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.13% | +0.01% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | BBIO | Bridgebio Pharma Inc | — | NEW | New buy |
| 2 | VRNA | Verona Pharma PLC - Adr | — | NEW | New buy |
| 3 | SNDX | Syndax Pharmaceuticals Inc | — | NEW | New buy |
| 4 | BCAX | Bicara Therapeutics Inc | — | NEW | New buy |
| 5 | GLUE | Monte Rosa Therapeutics Inc | — | NEW | New buy |
| 6 | NUVB | Nuvation Bio Inc | — | NEW | New buy |
| 7 | CMPS | Compass Pathways PLC | — | NEW | New buy |
| 8 | BMEA | Biomea Fusion Inc | — | NEW | New buy |
| 9 | CALC | Calcimedica Inc | — | NEW | New buy |
| 10 | ✓ | Elevation Oncology Inc | — | NEW | New buy |
| 11 | ACRS | Aclaris Therapeutics Inc | — | NEW | New buy |
| 12 | MRKR | Marker Therapeutics Inc | — | NEW | New buy |
| 13 | OKUR | Onkure Therapeutics Inc-a | — | NEW | New buy |
According to official SEC Form 13F filings, Aisling Capital Management LP reported a total U.S. public equity portfolio value of $471.6M across 13 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including BBIO, VRNA, SNDX) accounted for 58.5% of total reported equity market value during Q1 2025.
Top New Position Initiated
BBIO
市值: $209.8M
During Q1 2025, Aisling Capital Management LP's top holdings by market value included BBIO (72.7%)、VRNA (13.5%)、SNDX (4.4%). The largest single position, BBIO, represented 72.7% of total portfolio value.
In Q1 2025, Aisling Capital Management LP made 13 total portfolio adjustments, initiating 13 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.